David Bock, MD
Urology · Overland Park, KSNPI 1386693026
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,546 of the $5,651 with a category attached, or 80.5%. It is spread thinly across 38 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations.
Across 175 payments — averaging $32.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$988
- Johnson & Johnson$935
- Dendreon Pharmaceuticals LLC$516
- Bayer$422
- Astellas Pharma US Inc$388
- AbbVie$301
- plus $2K from 32 others
What the payments were for
- Travel & lodging$95417%
- Food & beverage$4,54680%
- Education$1513%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 5 | $988 |
| Johnson & Johnson | 43 | $935 |
| Dendreon Pharmaceuticals LLC | 5 | $516 |
| Bayer | 6 | $422 |
| Astellas Pharma US Inc | 19 | $388 |
| AbbVie(2 entities) | 18 | $301 |
| Histosonics, Inc. | 1 | $297 |
| Novartis | 7 | $271 |
| Pfizer | 16 | $238 |
| Progenics Pharmaceuticals, Inc. | 6 | $179 |
| Teleflex LLC | 2 | $135 |
| Urogen Pharma, Inc. | 3 | $99 |
| Coloplast | 6 | $85 |
| Amgen | 4 | $76 |
| Immunitybio, Inc. | 2 | $69 |
| Ferring Pharmaceuticals Inc. | 1 | $63 |
| Profound Medical Corp. | 1 | $58 |
| Agiliti Health, Inc. | 2 | $52 |
| Blue Earth Diagnostics | 3 | $45 |
| Innovation Technologies Inc | 1 | $39 |
| Boston Scientific | 2 | $38 |
| Convatec Inc. | 2 | $38 |
| Ambu Inc. | 2 | $35 |
| Olympus America Inc. | 2 | $32 |
| Urovant Sciences Inc | 2 | $27 |
| Tempus AI, Inc | 1 | $25 |
| Rochester Medical Corporation | 1 | $24 |
| Myriad Genetic Laboratories, Inc. | 2 | $24 |
| Antares Pharma, Inc. | 1 | $19 |
| Civco Medical Instruments | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Axonics, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Baudax Bio Inc. | 1 | $15 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Therapeuticsmd, Inc. | 1 | $12 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,651 in reported general payments places this provider in the 70th percentile of 111 urology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 93 | $83,349 |
| GemtesaVibegron | 68 | $74,617 |
| Tamsulosin Hcl | 700 | $11,524 |
| Silodosin | 47 | $5,286 |
| Finasteride | 439 | $5,108 |
| Potassium Citrate ErPotassium Citrate | 36 | $4,011 |
| Dutasteride | 62 | $2,288 |
| Estradiol | 17 | $1,328 |
| Desmopressin Acetate | 18 | $1,316 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 48 | $1,182 |
| Testosterone Cypionate | 18 | $918 |
| Oxybutynin Chloride | 13 | $550 |
| Terazosin Hcl | 28 | $345 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $270 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $388 | $83,34993 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 urology providers in Kansas.
Other urology in Overland Park
- Jason AnastOverland Park$31K
- Christian HettingerOverland Park$14K
- Nathaniel BallekOverland Park$11K
- Mirian BociOverland Park$7K
- Andrew FlumOverland Park$6K
- Andrew MorrisOverland Park$6K
- Lindsay HertzigOverland Park$3K
- Bradley DavisOverland Park$3K
- Timothy RichardsonWichita$493K
- Wilson MolinaKansas City$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.